BRCA2 Knockout cell line (LNCaP Clone FGC)
Catalog Number: KO00828
Price: Online Inquiry
Catalog Number: KO00828
Price: Online Inquiry
Product Information | |
---|---|
Product Name | BRCA2 Knockout cell line (LNCaP Clone FGC) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epithelioid, adherent cell |
Passage ratio | 1:2~1:3 |
species | Human |
Gene | BRCA2 |
Gene ID | 675 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 88%RPMI-1640+10% FBS+1%NEAA+1%Sodium pyruvate |
Parental Cell Line | LNCaP Clone FGC |
Quality Control | Genotype: BRCA2 Knockout cell line (LNCaP Clone FGC) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | BRCA2 DNA repair associatedprovided by HGNC |
Also known as | FAD; FACD; FAD1; GLM3; BRCC2; FANCD; PNCA2; FANCD1; XRCC11; BROVCA2 |
Gene Description | Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020] |
Expression | Broad expression in bone marrow (RPKM 2.9), testis (RPKM 2.2) and 17 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.